Table 7 The list of related studies
Years | Authors | Trial or research | Research design | Primary endpoint | RT/CRT Vs. RT/CRT + cetuximab | P value | Cancer |
|---|---|---|---|---|---|---|---|
2006 | Bonner JA et al. | NCT00004227 | RT(n = 213) Vs. RT + cetuximab(n = 211) | LR control (2 yr) | 41% Vs. 50% | 0.005 | HNSCC |
2014 | K. Kian Ang et al. | RTOG 0522 Phase III | CRT(n = 444) Vs. CRT + cetuximab(n = 447) | PFS (3 yr) | 61.2% Vs. 58.9% | 0.76 | HNSCC |
2016 | Xin Wu et al. | A retrospective matched case–control study | TPF + CRT(n = 56) Vs. TPF + RT + cetuximab(n = 56) | OS (5 yr) | 79.3% Vs. 79.5% | 0.797 | NPC |
2015 | T. Xu et al. | NCT01614938 Phase II | CRT(n = 23) Vs. RT + cetuximab(n = 21) | DFS (3 yr) | 78.3% Vs. 85.7% | 0.547 | NPC |